A proof of concept, biomarker-driven, multi-institution, phase II open label clinical trial is currently investigating the effectiveness of PARP inhibitor monotherapy (olaparib) to treat IDH mutant relapsed/refractory AML and MDS [154] (ClinicalTrials.gov Identifier: NCT03953898). Here, IDH2 is linked to acute myeloid leukemia.